Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 16/20 | 1.00 |
| ▸ | HTR6 | P50406 | 16/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Latrepirdine SCHEMBL29717663 | 1.00 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29357222 | 1.00 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717625 | 1.00 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL3733639 | 0.99 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717582 | 0.99 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL293658 | 0.99 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL30783244 | 0.99 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Dorastine SCHEMBL3264836 | 0.94 | HRH1 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL13320249 | 0.94 | HTR6 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL13320188 | 0.94 | HRH1 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | claimed |
| EP-2581374-B1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-03-19 | — | — | EP | claimed |
| EP-2417973-B1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO [4, 3-B]INDOLE DERIVATIVE | INST PHARM & TOXICOLOGY AMMS (CN) | 2013-08-28 | — | — | EP | claimed |
| EP-2581374-A1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2013-04-17 | — | — | EP | claimed |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA (CN) | 2012-05-17 | — | — | US | claimed |
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | Medivation Neurology ,Inc. | 2012-04-26 | — | — | US | claimed |
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | claimed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| EP-2417973-A1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2012-02-15 | — | — | EP | claimed |
| US-20110318345-A1 | NASAL DELIVERY | OPTINOSE AS (NO) | 2011-12-29 | — | — | US | claimed |
| WO-2008036410-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | MEDIVATION, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007087425-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | MEDIVATION NEUROLOGY,INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070179174-A1 | Methods and compositions for slowing aging | MEDIVATION, INC. | 2007-08-02 | — | — | US | claimed |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007041697-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (GB) | 2007-04-12 | — | — | WO | claimed |
| EP-1692131-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005055951-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| EP-0876818-B1 | AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS | SELENA PHARMACEUTICALS INC (US) | 2002-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | SLC6A3, DBH, GRIN3B | HRH1 2918/4885HTR6 4/4885ADRA2A 976/4885 |
| US-20070179174-A1 | Methods and compositions for slowing aging | PRDX5, HMOX1, SHMT2 | HRH1 2638/4885HTR6 80/4885ADRA2A 1913/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | HRH1 388/4885HTR6 3/4885ADRA2A 3695/4885 |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | HTT, HTR5A, HTR3B | HRH1 343/4885HTR6 7/4885ADRA2A 848/4885 |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | HRH1 388/4885HTR6 3/4885ADRA2A 3695/4885 |
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | TPH1, TPH2, HTR3B | HRH1 708/4885HTR6 11/4885ADRA2A 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.